ANDA 77751, held by Zydus Pharmaceuticals (USA). Pravastatin Sodium.
As of Nov 21, 2026, ANDA 77751 (Pravastatin Sodium), held by Zydus Pharmaceuticals (USA), was first approved by FDA on Apr 30, 2008, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 30, 2008 | Original application | Approved | None posted |
| Pravastatin Sodium10MG · tablet;oral | Pravastatin Sodium | Discontinued |
| Pravastatin Sodium20MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium40MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium80MG · tablet;oral | Pravastatin Sodium | Rx |
| Feb 18, 2025 | Supplement 22Labeling · Standard review | Approved | None posted |
| Nov 8, 2016 | Supplement 13Labeling · Standard review | Approved | None posted |
| Sep 16, 2015 | Supplement 11Labeling · Standard review | Approved | None posted |
| Sep 16, 2015 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 26, 2012 | Supplement 5Labeling | Approved | None posted |
| Jul 25, 2011 | Supplement 2Labeling | Approved | None posted |
| Apr 30, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters